New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both ...

Prostate cancer is the most commonly diagnosed cancer in New Zealand, and there are significant disparities in terms of diagnosis, treatment and outcomes. The funding pathway has so far enabled ...

An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of ...

In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients.

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Arthritis is identified as an independent risk factor for prostate cancer, with significant associations found in various analyses. The study utilized NHANES data and Mendelian randomization to ...

the radiotracer binds to prostate-specific membrane antigens (PSMA) expressed by the cancer cells. Following the same pathway, a therapy then targets the cancer cells, destroying them with ...

Metastasis-directed SABR has demonstrated benefit in oligometastatic castration-sensitive prostate cancer, but disease progression often occurs in bone. To assess whether adding Ra223 to SABR ...

A recurrence means that the prostate cancer has not been cured by the initial treatment. Surviving prostate cancer cells have become evident again on evaluation. Usually after surgery to remove ...